Skip to main content
. 2011 May 2;29(17):2410–2415. doi: 10.1200/JCO.2011.34.7542

Table 3.

Risk of AML/MDS Transformation According to No. of Cytoreductive Treatment Types

Treatment OR 95% CI
None 1.0 Ref
P32 only 1.5 0.8 to 2.8
Alkylating agent only 0.9 0.4 to 2.1
HU only 1.2 0.6 to 2.4
Mixed treatment (two or three) 2.9 1.4 to 5.9

Abbreviations: AML, acute myeloid leukemia; HU, hydroxyurea; MDS, myelodysplastic syndrome; OR, odds ratio; P32, radioactive phosphorus; Ref, reference.